These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 32100417)

  • 1. Novel risk group stratification for metastatic urothelial cancer patients treated with immune checkpoint inhibitors.
    Shabto JM; Martini DJ; Liu Y; Ravindranathan D; Brown J; Hitron EE; Russler GA; Caulfield S; Kissick H; Alemozaffar M; Ogan K; Harris WB; Master VA; Kucuk O; Carthon BC; Bilen MA
    Cancer Med; 2020 Apr; 9(8):2752-2760. PubMed ID: 32100417
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Modified Glasgow Prognostic Score associated with survival in metastatic renal cell carcinoma treated with immune checkpoint inhibitors.
    Brown JT; Liu Y; Shabto JM; Martini D; Ravindranathan D; Hitron EE; Russler GA; Caulfield S; Yantorni L; Joshi SS; Kissick H; Ogan K; Nazha B; Carthon BC; Kucuk O; Harris WB; Master VA; Bilen MA
    J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34326170
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Baseline Modified Glasgow Prognostic Score Associated with Survival in Metastatic Urothelial Carcinoma Treated with Immune Checkpoint Inhibitors.
    Brown JT; Liu Y; Shabto JM; Martini DJ; Ravindranathan D; Hitron EE; Russler GA; Caulfield S; Yantorni LB; Joshi SS; Kissick H; Ogan K; Harris WB; Carthon BC; Kucuk O; Master VA; Bilen MA
    Oncologist; 2021 May; 26(5):397-405. PubMed ID: 33634507
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Body Composition as an Independent Predictive and Prognostic Biomarker in Advanced Urothelial Carcinoma Patients Treated with Immune Checkpoint Inhibitors.
    Martini DJ; Shabto JM; Goyal S; Liu Y; Olsen TA; Evans ST; Magod BL; Ravindranathan D; Brown JT; Yantorni L; Russler GA; Caulfield S; Goldman JM; Nazha B; Joshi SS; Kissick HT; Ogan KE; Harris WB; Kucuk O; Carthon BC; Master VA; Bilen MA
    Oncologist; 2021 Dec; 26(12):1017-1025. PubMed ID: 34342095
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pre-first-line chemotherapy risk stratification for overall survival in advanced urothelial carcinoma in sequential therapy era.
    Shindo T; Hashimoto K; Fujino K; Takahashi A; Hotta H; Maeda T; Kunishima Y; Fukuta F; Ito N; Wanifuchi A; Kato R; Okada M; Matsukawa M; Horita H; Takayanagi A; Kobayashi K; Tanaka T; Masumori N
    World J Urol; 2024 May; 42(1):307. PubMed ID: 38722418
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel Risk Scoring System for Patients with Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors.
    Martini DJ; Liu Y; Shabto JM; Carthon BC; Hitron EE; Russler GA; Caulfield S; Kissick HT; Harris WB; Kucuk O; Master VA; Bilen MA
    Oncologist; 2020 Mar; 25(3):e484-e491. PubMed ID: 32162798
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical outcome after progressing to frontline and second-line Anti-PD-1/PD-L1 in advanced urothelial cancer.
    Gómez de Liaño Lista A; van Dijk N; de Velasco Oria de Rueda G; Necchi A; Lavaud P; Morales-Barrera R; Alonso Gordoa T; Maroto P; Ravaud A; Durán I; Szabados B; Castellano D; Giannatempo P; Loriot Y; Carles J; Anguera Palacios G; Lefort F; Raggi D; Gross Goupil M; Powles T; Van der Heijden MS
    Eur Urol; 2020 Feb; 77(2):269-276. PubMed ID: 31699525
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improving IMDC Prognostic Prediction Through Evaluation of Initial Site of Metastasis in Patients With Metastatic Renal Cell Carcinoma.
    Di Nunno V; Mollica V; Schiavina R; Nobili E; Fiorentino M; Brunocilla E; Ardizzoni A; Massari F
    Clin Genitourin Cancer; 2020 Apr; 18(2):e83-e90. PubMed ID: 31753738
    [TBL] [Abstract][Full Text] [Related]  

  • 9.
    de Kouchkovsky I; Zhang L; Philip EJ; Wright F; Kim DM; Natesan D; Kwon D; Ho H; Ho S; Chan E; Porten SP; Wong AC; Desai A; Huang FW; Chou J; Oh DY; Pruthi RS; Fong L; Small EJ; Friedlander TW; Koshkin VS
    J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 33980590
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sites of metastasis and association with clinical outcome in advanced stage cancer patients treated with immunotherapy.
    Bilen MA; Shabto JM; Martini DJ; Liu Y; Lewis C; Collins H; Akce M; Kissick H; Carthon BC; Shaib WL; Alese OB; Steuer CE; Wu C; Lawson DH; Kudchadkar R; Master VA; El-Rayes B; Ramalingam SS; Owonikoko TK; Harvey RD
    BMC Cancer; 2019 Aug; 19(1):857. PubMed ID: 31464611
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of performance status on treatment outcomes: A real-world study of advanced urothelial cancer treated with immune checkpoint inhibitors.
    Khaki AR; Li A; Diamantopoulos LN; Bilen MA; Santos V; Esther J; Morales-Barrera R; Devitt M; Nelson A; Hoimes CJ; Shreck E; Assi H; Gartrell BA; Sankin A; Rodriguez-Vida A; Lythgoe M; Pinato DJ; Drakaki A; Joshi M; Isaacsson Velho P; Hahn N; Liu S; Alonso Buznego L; Duran I; Moses M; Jain J; Murgic J; Baratam P; Barata P; Tripathi A; Zakharia Y; Galsky MD; Sonpavde G; Yu EY; Shankaran V; Lyman GH; Grivas P
    Cancer; 2020 Mar; 126(6):1208-1216. PubMed ID: 31829450
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effectiveness of First-line Immune Checkpoint Blockade Versus Carboplatin-based Chemotherapy for Metastatic Urothelial Cancer.
    Feld E; Harton J; Meropol NJ; Adamson BJS; Cohen A; Parikh RB; Galsky MD; Narayan V; Christodouleas J; Vaughn DJ; Hubbard RA; Mamtani R
    Eur Urol; 2019 Oct; 76(4):524-532. PubMed ID: 31362898
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk stratification for the prognosis of patients with chemoresistant urothelial cancer treated with pembrolizumab.
    Kobayashi T; Ito K; Kojima T; Kato M; Kanda S; Hatakeyama S; Matsui Y; Matsushita Y; Naito S; Shiga M; Miyake M; Muro Y; Nakanishi S; Kato Y; Shibuya T; Hayashi T; Yasumoto H; Yoshida T; Uemura M; Taoka R; Kamiyama M; Ogawa O; Kitamura H; Nishiyama H;
    Cancer Sci; 2021 Feb; 112(2):760-773. PubMed ID: 33283385
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A nomogram including baseline prognostic factors to estimate the activity of second-line therapy for advanced urothelial carcinoma.
    Pond GR; Agarwal N; Bellmunt J; Choueiri TK; Qu A; Fougeray R; Vaughn D; James ND; Salhi Y; Albers P; Niegisch G; Galsky MD; Wong YN; Ko YJ; Stadler WM; O'Donnell PH; Sridhar SS; Vogelzang NJ; Necchi A; Di Lorenzo G; Sternberg CN; Mehta A; Sonpavde G
    BJU Int; 2014 May; 113(5b):E137-43. PubMed ID: 24219029
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association Between Sites of Metastasis and Outcomes With Immune Checkpoint Inhibitors in Advanced Urothelial Carcinoma.
    Makrakis D; Talukder R; Lin GI; Diamantopoulos LN; Dawsey S; Gupta S; Carril-Ajuria L; Castellano D; de Kouchkovsky I; Koshkin VS; Park JJ; Alva A; Bilen MA; Stewart TF; McKay RR; Tripathi N; Agarwal N; Vather-Wu N; Zakharia Y; Morales-Barrera R; Devitt ME; Cortellini A; Fulgenzi CAM; Pinato DJ; Nelson A; Hoimes CJ; Gupta K; Gartrell BA; Sankin A; Tripathi A; Zakopoulou R; Bamias A; Murgic J; Fröbe A; Rodriguez-Vida A; Drakaki A; Liu S; Lu E; Kumar V; Lorenzo GD; Joshi M; Isaacsson-Velho P; Buznego LA; Duran I; Moses M; Jang A; Barata P; Sonpavde G; Yu EY; Montgomery RB; Grivas P; Khaki AR
    Clin Genitourin Cancer; 2022 Oct; 20(5):e440-e452. PubMed ID: 35778337
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Time from prior chemotherapy enhances prognostic risk grouping in the second-line setting of advanced urothelial carcinoma: a retrospective analysis of pooled, prospective phase 2 trials.
    Sonpavde G; Pond GR; Fougeray R; Choueiri TK; Qu AQ; Vaughn DJ; Niegisch G; Albers P; James ND; Wong YN; Ko YJ; Sridhar SS; Galsky MD; Petrylak DP; Vaishampayan UN; Khan A; Vogelzang NJ; Beer TM; Stadler WM; O'Donnell PH; Sternberg CN; Rosenberg JE; Bellmunt J
    Eur Urol; 2013 Apr; 63(4):717-23. PubMed ID: 23206856
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The efficacy of immune checkpoint inhibitors in advanced non-small-cell lung cancer with liver metastases.
    Kitadai R; Okuma Y; Hakozaki T; Hosomi Y
    J Cancer Res Clin Oncol; 2020 Mar; 146(3):777-785. PubMed ID: 31828427
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Patient-reported outcomes as a prognostic marker of survival in patients with advanced nonsmall cell lung cancer treated with immunotherapy.
    Hopkins AM; Wagner J; Kichenadasse G; Modi N; Rowland A; Sorich MJ
    Int J Cancer; 2020 Dec; 147(11):3085-3089. PubMed ID: 32492185
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association of Performance Status With Survival in Patients With Advanced Non-Small Cell Lung Cancer Treated With Pembrolizumab Monotherapy.
    Sehgal K; Gill RR; Widick P; Bindal P; McDonald DC; Shea M; Rangachari D; Costa DB
    JAMA Netw Open; 2021 Feb; 4(2):e2037120. PubMed ID: 33570575
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunotherapy and Sonpavde score validation in advanced upper tract urothelial carcinoma: a retrospective study by the Italian Network for Research in Urologic-Oncology (Meet-URO group).
    Bersanelli M; Mazzaschi G; Giannatempo P; Raggi D; Farè E; Maruzzo M; Basso U; De Giorgi U; Vignani F; Banna GL; Stellato M; Tambaro R; Naglieri E; Losanno T; Procopio G; Pignata S; Necchi A; Buti S
    Immunotherapy; 2022 Feb; 14(2):107-114. PubMed ID: 34784782
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.